The Cost Effectiveness of Early Treatment with Fluticasone Propionate 250 μ g Twice a Day in Subjects with Obstructive Airway Disease

Abstract

In a two-stage detection program, subjects with signs of obstructive airway disease were selected from a random sample of the general population. Subjects (n = 82) were randomly assigned to either fluticasone propionate 250 microg twice a day or placebo twice a day via pMDI in a 1-yr, double-blind trial if they met criteria for persistent airway obstruction, increased bronchial hyperresponsiveness, or a rapid decline in FEV(1). Main outcome measures were postbronchodilator FEV(1), quality-adjusted life years (QALYs), and direct medical cost. Secondary measures were prebronchodilator FEV(1), PC(20), health-related quality of life (CRQ), symptom-free weeks, episode-free weeks, exacerbations, and indirect cost. Subgroup analysis was based on reversibility of obstruction. Analysis revealed a significant gain in postbronchodilator FEV(1) (98 ml/yr; p = 0.01) in favor of fluticasone. Only subjects with reversible obstruction showed an improvement in PC(20) (1.4 doubling dose; p = 0.03). Early treatment resulted in 2.7 QALYs gained per 100 treated subjects (p = 0.17) and in a clinically relevant improvement in dyspnea (CRQ; p < 0.03). The incremental cost effectiveness ratios were US$13,016/QALY for early treatment and US$33,921/QALY for the combination of detection and treatment. The incremental cost for one additional subject with a clinically relevant difference in dyspnea was US$1,674. In conclusion, early intervention with fluticasone resulted in significant health gains at relatively low financial cost.

Outcomes for COPD pharmacological trials: from lung function to biomarkers

“…Test-retest reliability intra-class correlation coefficients of 0.73-0.95 and internal consistency reliability ranging 0.53-0.90 (Cronbach's alpha) have been reported [117,165,[448][449][450][451].…”

The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status

“…While most previous economic evaluations of asthma therapies have used either the cost per symptom day avoided or the cost per 0.5 unit change on the AQLQ(S) as a measure of cost effectiveness [17], only a limited number of studies have measured effectiveness in terms of QALYs [18][19][20][21][22][23]. A recent study, exploring the relationship between asthma control and HRQL, found that the EQ-5D was able to distinguish across levels of control [23].…”

Efficacy and Safety of a Monoclonal Antibody Recognizing Interleukin-8 in COPD

“…32 However, at least 6 months of treatment may be required to demonstrate the expected benefits in health status with pharmacologic therapy. 23,38 Rescue albuterol use was slightly lower (range, Ϫ 0.1 to Ϫ 0.4 puffs per day) in the active-treated group, compared to placebo. It is possible that the concomitant use of long-acting ␤-agonists and ipratropium bromide may have limited the utility of this end point.…”